Annovis Bio Ownership
| ANVS Stock | USD 1.78 0.15 7.77% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 11.3 M | Current Value 13 M | Avarage Shares Outstanding 7.2 M | Quarterly Volatility 2.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Annovis |
Annovis Stock Ownership Analysis
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.22. Annovis Bio had not issued any dividends in recent years. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people. For more info on Annovis Bio please contact Maria Maccecchini at 484 875 3192 or go to https://www.annovisbio.com.Besides selling stocks to institutional investors, Annovis Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Annovis Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Annovis Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Annovis Bio Quarterly Liabilities And Stockholders Equity |
|
About 14.0% of Annovis Bio are currently held by insiders. Unlike Annovis Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Annovis Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Annovis Bio's insider trades
Annovis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Annovis Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Annovis Bio backward and forwards among themselves. Annovis Bio's institutional investor refers to the entity that pools money to purchase Annovis Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-12-31 | 32.8 K | Greenwich Wealth Management Llc | 2024-12-31 | 32 K | Group One Trading, Lp | 2024-12-31 | 26.2 K | Sterling Investment Advisors Ltd | 2024-12-31 | 24 K | Bridgeway Capital Management, Llc | 2024-12-31 | 21.4 K | Spears Abacus Advisors Llc | 2024-12-31 | 20 K | Bank Of New York Mellon Corp | 2024-12-31 | 19.1 K | Lokken Investment Group Llc | 2024-12-31 | 18.2 K | Atria Wealth Solutions, Inc. | 2024-12-31 | 13 K | Vanguard Group Inc | 2024-12-31 | 466.3 K | Citadel Advisors Llc | 2024-12-31 | 215.2 K |
Annovis Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Annovis Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Annovis Bio Outstanding Bonds
Annovis Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Annovis Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Annovis bonds can be classified according to their maturity, which is the date when Annovis Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.